Prescribing Clinical Network

<table>
<thead>
<tr>
<th>Policy Statement</th>
<th>Dosulepin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>PCN 314-2018</td>
</tr>
<tr>
<td>Date of Issue</td>
<td>January - 2018</td>
</tr>
<tr>
<td>Review Date</td>
<td>January - 2021</td>
</tr>
</tbody>
</table>

(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

Recommendations:
The Prescribing Clinical Network does not recommend the use of dosulepin

Dosulepin will be considered BLACK on the traffic light system, prescribers should:

- NOT initiate dosulepin for any new patient; AND
- Switch patients taking dosulepin to an alternative antidepressant

In exceptional circumstances where there is a clinical need for dosulepin to be prescribed in primary care this should be undertaken in a cooperation arrangement with a multidisciplinary team and / or other healthcare professional

Key Considerations:

- Evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose

Date taken to Prescribing Clinical Network | 10th January 2018
Agreed by PCN members | 22nd January 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG